Phase 2 trial to study the effect of KTN-3379 for the treatment of patients with recurrent/metastatic head and neck squamous cell cancer who are refractory to cetuximab
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs CDX-3379 (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 08 Aug 2017 According to a Koltan Pharmaceuticals media release, the company expects to initiate this study in the fourth quarter of 2017.
- 18 May 2016 According to a Koltan Pharmaceuticals media release, this trial is expected to start in the year 2016.
- 25 Apr 2016 New trial record